Cephalalgia : an international journal of headache
-
Randomized Controlled Trial Multicenter Study
Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study.
Menstrually related migraine (MRM) affects more than half of female migraineurs. Because such migraines are often predictable, they provide a suitable target for treatment in the mild pain phase. The present study was designed to provide prospective data on the efficacy of almotriptan for treatment of MRM. ⋯ Almotriptan was significantly more effective than placebo in women with MRM attacks, with consistent efficacy in longer-term follow-up.
-
Randomized Controlled Trial Multicenter Study
Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study.
The study sought to evaluate whether topiramate prevents development of chronic daily headache (CDH, ≥15 headache days per month) in adult subjects with high-frequency episodic migraine (HFEM, 9-14 migraine headache days/month). A secondary objective was to assess the efficacy of topiramate as preventive migraine treatment in this population. ⋯ Topiramate 100 mg/day did not prevent the development of CDH at six months in subjects with HFEM. Topiramate was effective in reducing headache days and migraine headache days and generally well tolerated.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Effectiveness of manual therapy for chronic tension-type headache: a pragmatic, randomised, clinical trial.
-
To determine if migraineurs have evidence of interictal cutaneous sensitisation. ⋯ Interictal sensitisation may predispose the migraineur to development of headaches, may be a marker of migraine activity, and a target for treatment.